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Background: Cardiogenic shock is a serious complication of a ST-segment elevation myocardial infarction
(STEMI). We compared short- and long-termmortality among (1) STEMI patients with and without cardiogenic
shock and (2) STEMI patients with cardiogenic shock with and without the use of an intra-aortic balloon pump
(IABP).
Methods: From January 1, 2002 to December 31, 2010, all patients presenting with STEMI and treated with pri-
mary percutaneous coronary intervention (PCI) were identiﬁed. The hazard ratio (HR) for death was estimated
using a Cox regression model, controlling for potential confounding.
Results: The study cohort consisted of 4293 STEMI patients: 286 (6.7%)with and 4007 (93.3%)without cardiogen-
ic shock. Compared with patients without cardiogenic shock, patients with cardiogenic shock were older, and
more likely to have diabetes mellitus, multi-vessel disease, anterior myocardial infarction (MI) or bundle-
branch block MI and a reduced creatinine clearance.
Among patients with cardiogenic shock vs. without shock, 30-day cumulative mortality was 57.3% vs. 4.5%
(p b 0.001), one-year cumulative mortality was 60.7% vs. 8.2% (p b 0.001) and ﬁve-year mortality was 65.0% vs.
18.9% (p b 0.001). STEMI with cardiogenic shock was associated with higher 30-day mortality (adjusted HR =
12.89 [95% CI: 9.72–16.66]), 1-year mortality (adjusted HR= 8.83 [95% CI: 7.06–11.05]) and ﬁve-year mortality
(adjusted HR = 6.39 [95% CI: 5.22–7.80]). IABP was used in 71 (25%) patients with cardiogenic shock and was
associated with improved 30-day outcome (adjusted HR= 0.48 [95% CI: 0.28–0.83]).
Conclusion: Patients with STEMI and cardiogenic shock had substantial short- and long-termmortality that may
be improved with IABP implantation. More studies on use of IABP in such patients are warranted.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Although the treatment of acute myocardial infarction (MI) has im-
proved over the years, the mortality of patients in cardiogenic shock
complicating MI remains high even with the use of primary percutane-
ous coronary intervention (PCI) and has not changed in decades [1,2].
However, over the past decade, rates of cardiogenic shock developing
during hospitalization as well as in-hospital mortality associated with
shock have decreased; increased PCI rates for these critically ill patients
may explain these secular trends [3].
Beyond the use of PCI, intra-aortic balloon pump (IABP) implanta-
tion has widely been used as an adjuvant treatment for cardiogenic
shock in patients with acute MI based on the beneﬁcial effect of aortic
diastolic inﬂation and rapid systolic deﬂation, improving myocardial
and peripheral perfusion and reducing afterload andmyocardial oxygen
consumption [4,5]. The evidence base supporting IABP in cardiogenic
shock use is mixed; in a recent meta-analysis [6], the use of IABP in pa-
tients with ST-segment elevation MI (STEMI) with cardiogenic shock
treated was associated with a survival beneﬁt [6]. However, on an indi-
vidual level the data are less clearly supportive [7]. Notably, a random-
ized trial, the Intraaortic Balloon Support for Myocardial Infarction
with Cardiogenic Shock (IABP-SHOCK II) study showed no improve-
ment in survival using IABP in patients with MI and cardiogenic shock
[8]. However, in this trial the patients represented a rather moderate-
risk cohort with a substantially lower short-term mortality compared
to those in other trials [2,9]. Additionally, in IABP-SHOCK II, there was
observed a favorable trend with IABP in younger patients and in those
with a ﬁrst MI. Accordingly, in an effort to examine this question in
more detail, we used data from the Western Denmark Heart Registry
(WDHR) to compare short- and long-term mortality among (A) STEMI
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patients with and without cardiogenic shock and (B) STEMI patients
with cardiogenic shockwith and without the use of IABP. It was our hy-
pothesis that risk for mortality related to cardiogenic shock in this “real
world” cohort of patients would be substantial, and that IABP usewould
reduce risk signiﬁcantly compared to conservative management with-
out IABP.
2. Patients and methods
2.1. Setting and design
The study was conducted using WDHR for patients treated at
Odense University Hospital with a catchment population of 1.2 million
inhabitants. A detailed description of the database has been reported
previously [10].
2.2. Patients and procedures
Primary PCI became the recommended treatment for STEMI in
Denmark in 2003 after pivotal trials supported this approach [11]. To
be eligible for primary PCI, patients must generally meet the following
criteria: 1) symptoms present less than 12 h from onset of pain to
time of catheterization, and 2) ST-segment elevation (at least 0.1 mV
in two or more standard leads or v4–v6, or at least 0.2 mV in two or
more contiguous precordial leads (v1–v3) or a presumed new left
bundle-branch block. We used the WDHR to identify all primary PCIs
performed from January 1, 2002 through December 31, 2010. A patient
was considered in cardiogenic shock if systolic blood pressure was
b90 mm Hg with the need of infusion of catecholamines to maintain
the blood pressure, had clinical signs of pulmonary congestion, and
had impaired end-organ perfusion (cold, clammy skin, altered mental
status) or the use of IABP within the ﬁrst 24 h of admission. Primary
PCI was performed according to the standard. A glycoprotein IIb/IIIa re-
ceptor blocker was administered at the operator's discretion. The post-
intervention antiplatelet regimen included lifelong acetylsalicylic acid
(75 mg once daily) and clopidogrel with a loading dose of 300 mg
followed bymaintenancewith 75mgdaily. The recommended duration
of clopidogrel treatment was 12 months.
2.3. Endpoints
The endpoint was time to all-cause mortality. Data on mortality sta-
tus were obtained from the Danish Civil Registration System; this sys-
tem has data to support accuracy [12,13].
The Danish National Health Service provides universal tax-
supported health care, guaranteeing residents free access to general
practitioners and hospitals. The Danish Civil Registration System has
kept electronic records on gender, birth date, residence, emigration
date, and vital status changes since 1968, with daily updates; the 10-
digit civil registration number assigned at birth and used in all registries
allows for accurate record linkage. The Civil Registration System provid-
ed vital status data for our study participants and minimized loss to
follow-up.
2.4. Statistical methods
Continuous variables were presented as medians with inter quartile
range (IQR 25th, 75th) or mean± 1 standard deviations (SD). Medians
were compared using theMann–Whitney U test, andmeans were com-
pared using the unpaired t test. Categorical variables were presented as
numbers and percentages. Distributions of categorical variables were
compared using the Chi-square test. We counted endpoint events that
occurred during the follow-up period and compared rates for the two
groups. Follow-up began on the date of primary PCI procedure and
continued until date of death, December 31, 2010 or after 5 of years
follow-up (to ensure at least 10% of the studypopulation at risk),which-
ever came ﬁrst.
We constructed Kaplan–Meier curves for patients with cardiogenic
shock and without cardiogenic shock, and patients with cardiogenic
shock were stratiﬁed according to treatment with an IABP or not. Cox
proportional hazards regression analysis was used to estimate the
hazard ratio (HR) for mortality. Crude and adjusted hazard ratios
(HRs) with 95% conﬁdence intervals (CIs) were computed. Potential
confounders associated with time to death in the univariable Cox re-
gression analysis were included in the multivariable Cox regression
model. Thus, in the ﬁnal model, we adjusted for age, gender, diabetes
mellitus, previous MI, creatinine clearance b60 mL/min, treatment
with glycoprotein IIb/IIIa receptor blocker, anterior MI/bundle-branch
blockMI,multivessel disease andprocedure time. All data analyseswere
carried out using SPSS software version 20. A two-sided p value b 0.05
was considered signiﬁcant.
3. Results
3.1. Study population
A total of 4601 consecutive patients were treated with primary PCI
for STEMI or bundle-branch block MI at Odense University Hospital
between January 1, 2002 and December 31, 2010. Mortality data were
not available for 85 patients, who were foreign citizens and were ex-
cluded. Patients undergoing a later primary PCI for acute MI after the
ﬁrst index procedure (n=223)were excluded. Thus, the ﬁnal study co-
hort consisted of 4293 patients, of whom 286 (6.7%) had cardiogenic
shock and 4007 (93.3%) were without cardiogenic shock.
Baseline characteristics of patients with STEMI and cardiogenic
shock and patients without cardiogenic shock are shown in Table 1.
There were differences in several baseline characteristics and risk fac-
tors between STEMI patients with and without cardiogenic shock, as
patients with STEMI and cardiogenic shock were older, and more likely
to have diabetesmellitus, reduced creatinine clearance, previousMI and
previous CABG. Also, patients with cardiogenic shock more often had
multi-vessel disease, anterior MI or bundle-branch block MI, a lower
pre and post intervention TIMI ﬂow and a longer procedure time
(Table 2).
Among STEMI patients with cardiogenic shock, IABP was used in 71
(25%) patients. STEMI patientswith cardiogenic shock treatedwith IABP
were younger, more oftenmale, and had a lower systolic blood pressure
compared to patients with cardiogenic shock without IABP treatment
(Table 1).
3.2. Mortality
Themedian follow-up interval was 3.3 years (25th–75th percentile:
1.4–5.0 years), with a 30-day cumulative mortality of 8.0% (n = 495),
one-year mortality of 495 (11.7%) and ﬁve-year mortality of 22.0%
(n = 768). Among patients with STEMI with cardiogenic shock and
without cardiogenic shock, 30-day cumulative mortality was 57.3%
(n = 164) and 4.5% (n = 179), respectively (log-rank p b 0.001); one-
year cumulative mortality was 60.7% (n = 173) and 8.2% (n = 322),
respectively (log-rank p b 0.001); ﬁve-year cumulative mortality
was 65.0% (n = 181) and 18.9% (n = 587), respectively (log-rank
p b 0.001). Short and long term cumulative survival are shown in
Fig. 1. After adjustment for covariates associated with mortality (see
Statistical methods), STEMI with cardiogenic shock was associated
with increased mortality compared to STEMI without cardiogenic
shock after 30 days [adjusted HR = 12.89, 95% CI: 9.97–16.66], one-
year [adjusted HR = 8.83, 95% CI: 7.06–11.05] and ﬁve-year [adjusted
HR= 6.39, 95% CI: 5.22–7.81] (Table 3).
When stratifying patients with STEMI and cardiogenic shock into
two groups with (1) treatment with IABP and (2) no treatment with
IABP cumulative mortality rates were: 30-day cumulative
20 J.K. Jensen et al. / IJC Heart & Vasculature 6 (2015) 19–24
mortality was 32.4% (n = 23) and 65.6% (n = 141), respectively (log-
rank p b 0.001); one-year cumulative mortality was 33.8% (n = 24)
and 69.9% (n = 149), respectively (log-rank p b 0.001); and ﬁve-year
cumulative mortality was 48.8% (n= 26) and 73.4% (n= 155), respec-
tively (log-rank p b 0.001). Short term cumulative survival is shown in
Fig. 2. After adjustment for covariates, treatment with IABP in patients
with STEMI and cardiogenic shock was associated with a lower mortal-
ity compared to STEMI with cardiogenic shock without IABP support
after 30 days [adjusted HR= 0.45, 95% CI: 0.26–0.79], one-year [adjust-
ed HR= 0.48, 95% CI: 0.28–0.83] and ﬁve-year [adjusted HR= 0.5, 95%
CI: 0.30–0.85].
4. Discussion
In studies of cardiogenic shock complicating STEMI, rates of mor-
tality vary widely [4]. Additionally, reported efﬁcacy of widely used
therapies such as IABP in these studies has been variable [4,14]. How-
ever, current guidelines of the European Society of Cardiology have
downgraded IABP use in patients with cardiogenic shock complicated
by myocardial infarction (class 2B) [5]. The downgrading is primarily
due to the results from the IABP-SHOCK II trial [8]. Despite this fact,
IABP use remains in wide use, driven by substantial anecdotal evidence
as well as meta-analytic results [6].
Our study indicates that among STEMI patients treatedwith primary
PCI in a realworld clinical setting, the presence of cardiogenic shockwas
associated with increased short-and long-term mortality compared to
STEMI patientswithout cardiogenic shock. Importantly, use of IABP sup-
port in STEMI patients with cardiogenic shock was associated with sig-
niﬁcantly reduced mortality.
The incidence of cardiogenic shock was 6.7% in our registry, which
included all consecutive STEMI patients treated with primary PCI, was
similar to the results of several previous studies [1,15]. Additionally,
overall 30-day and 5-year mortality rate of ~60% is in accordance with
other studies [1,2,9,15], and in linewith the assumption that the highest
mortality of cardiogenic shock is during the ﬁrst weeks after the shock
appears. Importantly, 30-day mortality rate of 57% in our study was
considerably higher compared to the results from IABP-SHOCK II trial,
which had 30-day mortality of ~40% [8]. The higher mortality in our
study may reﬂect a high risk cohort e.g. there was a high number of
patients with left main disease in cardiogenic shock needing IABP.
IABP-SHOCK IIwas theﬁrst adequately powered randomized controlled
study of 600 patients with cardiogenic shock complicating acute MI. In
this randomized multicenter study, the patients in cardiogenic shock
underwent early revascularization, best medical therapy and were
randomly assigned to IABP. In the IABP-SHOCK II trial [8], there was
no difference in 30-day mortality, renal function or attenuation in
lactate or C-reactive protein levels between patients treated with
IABP compared to those without [8]. However, important caveats re-
garding differences between our study and IABP-SHOCK II exist. For
example, a quarter of the patients in IABP-SHOCK II had serum lactate
b2.0 mmol/L which indicates that the patients represented a moderate-
risk cohort and ~10%of the patients randomized to optimalmedical ther-
apy had a cross-over and were treated with an IABP.
The mortality reduction of IABP in our study is in line with a recent
meta-analysis which included prospective and retrospective cohort
studies [6]. In contrast, analyzing data from the Euro Heart Survey Pro-
gramme (EHS PCI) from the European Society of Cardiology including
653 patients with STEMI and non-STEMI, Zeymer et al. reported higher
in-hospital mortality in the 25% of cardiogenic shock patients treated
with IABP in comparison to the non-IABP group (56.9% versus 36.1%,
p = 0.0004). In multivariate analysis including parameters such as
age, gender, mechanical ventilation, severity of coronary artery disease,
diabetes, renal failure and history of prior myocardial infarction, IABP
use was not independently associated with mortality, although the
corresponding p-value of 0.07 can be interpreted as a trend [16]. This
is in contrast to our registry results, the opposite was found with aTa
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Table 2
Procedure characteristics of STEMI patients with cardiogenic shock versus without cardiogenic shock.
With cardiogenic
shock
Valid
cases
Without cardiogenic
shock
Valid
cases
p value (with vs.
without cardiogenic
shock)
With cardiogenic
shock and without
IABP
With cardiogenic
shock and with IABP
p value (cardiogenic
shock with versus
without IABP)
Number of patients 286 4007 215 71
Infarct related artery — no. (%) 275 3901 b0.001 0.021
Left anterior descending artery — no. (%) 110 (40.0) 1679 (43.0) 81 (39.3) 29 (42.0)
Left circumﬂex artery — no. (%) 30 (10.9) 552 (14.2) 25 (12.1) 5 (7.2)
Right coronary artery — no. (%) 78 (28.4) 1605 (41.1) 65 (31.3) 13 (18.8)
Left main — no. (%) 57 (20.7) 65 (1.7) 35 (17.0) 22 (31.9)
Anterior STEMIa or BBBMIb — no. (%) 155 (56.6) 275 1687 (43.8) 4366 b0.001 108 (52.4) 47 (69.1) 0.016
Multivessel disease — no. (%) 184 (67.4) 273 1722 (44.1) 3903 b0.001 142 (48.3) 42 (64.6) 0.519
Pre-intervention TIMI ﬂow — no. (%) 273 4038 0.010 0.016
Grade 0 170 (62.3) 2134 (54.8) 124 (60.8) 46 (66.7)
Grade 1 21 (7.7) 243 (6.2) 11 (5.4) 10 (14.5)
Grade 2 28 (10.3) 674 (17.3) 22 (10.8) 6 (8.7)
Grade 3 54 (19.8) 846 (21.7) 42 (23.0) 7 (10.1)
Final TIMI ﬂow — no. (%) 273 3897 b0.001 0.156
Grade 0 22 (8.1) 111 (2.8) 18 (8.8) 4 (5.8)
Grade 1 11 (4.0) 42 (1.1) 11 (5.4) 0 (0.0)
Grade 2 11 (11.4) 225 (5.8) 21 (10.3) 10 (14.5)
Grade 3 209 (76.6) 3519 (90.3) 154 (75.5) 55 (79.7)
Lesion length —mm 15.0 (10.0–20.0) 270 15.0 (10.0–20.0) 4001 0.359 15.0 (10.0–20.0) 15.0 (10.0–20.0) 0.485
Reference segment —mm 3.4 (3.0–3.8) 269 3.2 (3.0–3.6) 3965 0.084 3.2 (3.0–3.6) 3.5 (3.1–3.8) 0.001
Sapheneous vein graft — no. (%) 0 (0.0) 274 14 (0.4) 3902 0.321 0 (0.0) 0 (0.0) –
Stent length —mm 18.0 (13.0–23.0) 238 18.0 (14.0–23.0) 3621 0.737 18.0 (13.0–24.0) 18.0 (15.0–23.0) 0.280
Type of stent — no. (%) 285 3952 0.203 0.005
POBA only 49 (17.2) 417 (10.6) 40 (18.6) 9 (12.7)
Bare metal stent 103 (36.1) 1229 (31.1) 86 (40.2) 17 (23.9)
Drug eluting stent 133 (46.7) 2306 (58.4) 88 (41.1) 45 (63.9)
Max balloon pressure — atm 16.0 (14.0–18.0) 261 16.0 (14.0–18.0) 3786 0.614 16.0 (14.0–18.0) 16.0 (14.0–18.0) 0.792
Max balloon diameter —mm 3.5 (3.2–3.8) 261 3.5 (3.2–3.8) 3784 0.944 3.4 (3.2–3.8) 3.7 (3.3–4.0) 0.004
Procedure time —minutes (inter-quartile range) 21.0 (15.0–41.0) 285 16.0 (10.0–26.0) 3991 b0.001 20.0 (13.0–34.0) 30.5 (19.0–51.0) b0.001
Flouro time —minutes (inter-quartile range) 8.4 (5.5–15.1) 273 6.6 (4.0–11.5) 3954 b0.001 7.9 (5.1–14.9) 10.1 (6.4–16.1) 0.048
Contrast —mL (inter-quartile range) 110.0 (79.0–200.0) 4731 100 (75.0–175.0) 3937 0.115 100.0 (70.0–200.0) 135.0 (100.0–200.0) 0.052
a ST-segment elevation myocardial infarct.
b Left bundle branch block.
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signiﬁcant lowermortality rate in cardiogenic shock patients supported
with IABP. Of course, important selection bias may be present in both
registries e.g. operator's discretion for using IABP, the deﬁnition of car-
diogenic shock, and difference in baseline characteristics of the patients.
It is worthwhile to discuss 30-day and 1 year mortality of patients
with and without cardiogenic shock in our analysis. In-hospital mortality
after STEMI in patients without cardiogenic shock has been reduced to
b10% in the last decades [17]. This is mainly attributable to optimal inter-
ventional and drug treatment in the acute and subacute phase; indeedwe
observed quite similar results. In contrast to the clinical outcome in STEMI
patients with hemodynamic stability, 30-day mortality of cardiogenic
shock complicating STEMI remains high with rates of approximately
50% [1]. Thus, mortality related to cardiogenic shock has not changed
substantially in nearly two decades [2], and studies focused on improved
myocardial support, reperfusion, and protection in this population
are critically needed. One option is alternative modes of support, such
as the use of percutaneous left ventricular assist devices (LVAD).
The prospective, randomized, open-label, multicenter, controlled Danish
Cardiogenic Shock Trial (DanShock) [ClinicalTrials.gov identiﬁer:
NCT01633502] is ongoing and will assess whether the Impella cVAD™
LVAD treatment is beneﬁcial for the treatment of cardiogenic shock.
4.1. Limitations
The validity of ourﬁndings depends ondata quality and the ability to
control for potential confounding. Like all observational studies, our
study is prone to biases related to unmeasured factors. Bias due to un-
known variables cannot be eliminated e.g. peripheral vascular disease
or smaller peripheral vasculature. Our design is based on computerized
registries with complete coverage, allowing study of a well-deﬁned,
large populationwith complete follow-up. That said, within the context
of these limitations, it would appear that selection of patients to receive
IABP support in our dataset led to more favorable outcomes, indeed a
ﬁnding worth pointing out. We did not have systematic access to dura-
tion of inotropic support, serum lactate or information about left ven-
tricular ejection fraction. We also lacked data on causes of mortality,
however, in a previous STEMI cohort fromWesternDenmarkHeart Reg-
istry, we found early causes of death were typically due to a cardiac rea-
son: the 1-year mortality reason was cardiac in the great majority [18].
5. Conclusion
In STEMI patients, cardiogenic shock was associated with increased
short- and long-term mortality compared to STEMI patients without
cardiogenic shock. IABP balloon support in STEMI patients with cardio-
genic shock was associated with improved outcome. Given that the
mortality rate of those suffering cardiogenic shock after STEMI has not
changed substantially over the past 2 decades, more studies focused
on the optimal care of this high-risk patient population are warranted.
Conﬂict of interest
The authors report no relationships that could be construed as a con-
ﬂict of interest.
Table 3
Crude and adjusted hazard ratio of covariates associated with one-year mortality in Cox regression analysis.
Valid cases Crude hazard ratio
(95% CI)
p value Adjusted hazard ratio
(95% CI)
p value
Cardiogenic shock 13.04 (10.82–15.72) b0.001 8.80 (7.06–11.05) b0.001
Female gender 4116 1.50 (1.25–1.81) b0.001 0.96 (0.78–1.06) 0.683
Creatinine clearance b 60 mL/min 4116 4.83 (4.05–5.76) b0.001 1.90 (1.53–2.37) b0.001
Age — years 4116 1.07 (1.06–1.08) b0.001 1.05 (1.04–1.06) b0.001
Diabetes mellitus 4116 2.30 (1.83–2.87) b0.001 1.90 (1.47–2.46) b0.001
Previous myocardial infarction 4043 1.91 (1.52–2.40) b0.001 1.56 (1.19–2.05) 0.001
Glycoprotein IIb/IIIa receptor blocker 3826 0.46 (0.38–0.57) b0.001 0.66 (0.53–0.82) b0.001
Multivessel disease 4011 2.50 (2.07–3.01) b0.001 1.44 (1.15–1.79) 0.001
Anterior MI/BBBMI 4011 1.35 (1.13–1.62) b0.001 1.23 (1.03–1.53) 0.022
Procedure time —minutes 4100 1.01 (1.01–1.02) b0.001 1.00 (1.00–1.01) 0.166
Fig. 2. Kaplan–Meier survival curves for consecutive patients with STEMI and cardiogenic
shock with and without the use of intra-aortic balloon pump.
Fig. 1. Kaplan–Meier survival curves for consecutive patients with STEMI with and with-
out cardiogenic shock.
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